review · RSC Advances
Silver nanoparticle-polymer nanocomposites combine antimicrobial action with the structural versatility of polymer matrices. These hybrid materials offer enhanced infection control, mechanical stability, and controlled drug delivery, showing relevance for wound healing, medical coatings, tissue engineering, and biosensors. Recent refinements in synthesis and functionalisation have yielded improved control over nanoparticle morphology, dispersion, and stability. However, translational and clinical progress is impeded by cytotoxicity, uncertain long-term stability, adverse immune responses, and difficulties with manufacturing scalability. Resolving these limitations requires systematic advancements in hybridization strategies, surface functionalisation, and biocompatibility evaluations. Realising the potential of these nanocomposites in clinical settings also depends on navigating clear translational pathways and adhering to rigorous regulatory frameworks such as FDA and EMA requirements.
Infection control and material failure remain critical problems in healthcare. Integrating antimicrobial silver nanoparticles into polymer materials creates versatile systems that protect against pathogens while delivering therapies. Overcoming safety hurdles like toxicity and satisfying international regulatory standards are vital steps towards deploying these next-generation materials in hospitals, wound clinics, and advanced diagnostic devices.
Potential applications include wound dressings, medical device coatings, tissue scaffolds, and biosensors, targeted at healthcare providers and medical technology manufacturers. The field remains in a preclinical and translational phase. Commercialisation is constrained by unresolved cytotoxicity, immune reaction risks, and scalability challenges, alongside the need to satisfy stringent regulatory compliance under FDA and EMA guidelines before clinical deployment can occur.
AI-generated from the published abstract. Always read the original work before citing.
Silver nanoparticle-polymer nanocomposites (AgNP-PNCs) represent a transformative advancement in biomedical material science, integrating the potent antimicrobial properties of AgNPs with the structural versatility of polymer matrices. This synergy enables enhanced infection control, mechanical stability, and controlled drug delivery, making these nanocomposites highly suitable for applications such as wound healing, medical coatings, tissue engineering, and biosensors. Recent progress in synthesis and functionalization has led to greater control over particle morphology, dispersion, and stability, optimizing AgNP-PNCs for clinical and translational applications. However, challenges related to cytotoxicity, long-term stability, immune response, and scalability persist, necessitating systematic improvements in surface functionalization, hybridization strategies, and biocompatibility assessments. This review critically evaluates the latest advancements in AgNP-PNC development, focusing on their functionalization techniques, regulatory considerations, and emerging strategies to overcome biomedical challenges. Additionally, it discusses preclinical and translational aspects, including commercialization barriers and regulatory frameworks such as FDA and EMA guidelines, ensuring a comprehensive outlook on their clinical feasibility. By bridging the gap between innovation and practical application, this review investigates the transformative potential of AgNP-PNCs in advancing next-generation biomedical materials.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1039/d4ra08220f
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
